Cargando…

Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine—Clinical Considerations: A Narrative Review

Calcitonin gene-related peptide (CGRP) is involved in several of the pathophysiologic processes underpinning migraine attacks. Therapies that target CGRP or its receptor have shown efficacy as preventive or acute treatments for migraine. Two small-molecule CGRP receptor antagonists (rimegepant and u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ailani, Jessica, Kaiser, Eric A., Mathew, Paul G., McAllister, Peter, Russo, Andrew F., Vélez, Christopher, Ramajo, Angela Pozo, Abdrabboh, Ahmad, Xu, Cen, Rasmussen, Soeren, Tepper, Stewart J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651456/ https://www.ncbi.nlm.nih.gov/pubmed/36127137 http://dx.doi.org/10.1212/WNL.0000000000201332

Ejemplares similares

A narrative review of the importance of pharmacokinetics and drug–drug interactions of preventive therapies in migraine management
por: Joshi, Shivang, et al.
Publicado: (2021)

Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data
por: Dodick, David W., et al.
Publicado: (2021)

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond
por: Garelja, Michael L., et al.
Publicado: (2022)

Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study
por: Tepper, Stewart J., et al.
Publicado: (2021)

Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States
por: Tepper, Stewart J, et al.
Publicado: (2021)

The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review
por: Ailani, Jessica, et al.
Publicado: (2023)

Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure
por: Tepper, Stewart J., et al.
Publicado: (2022)

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review
por: Blumenfeld, Andrew M., et al.
Publicado: (2023)

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2022)

Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2023)

Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review
por: Jiang, Yan, et al.
Publicado: (2022)

Calcitonin gene-related peptide causes migraine aura
por: Al-Khazali, Haidar M., et al.
Publicado: (2023)

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
por: Fila, Michal, et al.
Publicado: (2023)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study
por: Kawata, Ariane K., et al.
Publicado: (2021)

Pharmacovigilance: reporting requirements throughout a product’s lifecycle
por: Lucas, Sylvia, et al.
Publicado: (2022)

Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
por: Schoenen, Jean, et al.
Publicado: (2023)

Epigenetic Connection of the Calcitonin Gene-Related Peptide and Its Potential in Migraine
por: Fila, Michal, et al.
Publicado: (2022)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
por: McAllister, Peter, et al.
Publicado: (2022)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment
por: MaassenVanDenBrink, Antoinette, et al.
Publicado: (2018)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

Prophylaxis of migraine: general principles and patient acceptance
por: D’Amico, Domenico, et al.
Publicado: (2008)

The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression
por: Tepper, Stewart J., et al.
Publicado: (2023)

Strategies of care for acute treatment of migraine
por: Tepper, Stewart J., et al.
Publicado: (2002)

Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients
por: Lassen, L. H., et al.
Publicado: (2008)

Association of Serum Levels of Calcitonin Gene-related Peptide and Cytokines during Migraine Attacks
por: Han, Dawei
Publicado: (2019)

The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine
por: Iyengar, Smriti, et al.
Publicado: (2017)

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Plasma calcitonin gene‐related peptide (CGRP) in migraine and endometriosis during the menstrual cycle
por: Raffaelli, Bianca, et al.
Publicado: (2021)

Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults
por: Ocheretyaner, Eric R, et al.
Publicado: (2022)

Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review
por: Shah, Tulsi, et al.
Publicado: (2023)

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
por: McAllister, Peter, et al.
Publicado: (2022)

Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
por: Tepper, Stewart J., et al.
Publicado: (2022)

Inpatient Constipation Among Migraine Patients Prescribed Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies and Standard of Care Antiepileptic Drugs: A Retrospective Cohort Study in a United States Electronic Health Record Database
por: Chomistek, Andrea K., et al.
Publicado: (2022)

Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
por: Tepper, Stewart J., et al.
Publicado: (2022)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide’s Motor-Stimulating and Prosecretory Function in the Intestine
por: Holzer, Peter, et al.
Publicado: (2022)

Network Meta-Analysis of Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine
por: Xu, Fang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_43q102gihub3ot8v4rnlrk34nu